The Lefts Brilliantly Deceptive Documentary Alt-Right …

One of the biggest goals of the left in recent years is to portray those on the right as racists. It saves them the effort of having to refute the rights arguments substantively. If they are successful, they can discredit all of the rights viewpoints since theyre views held by racists. There are few white supremacists left, but the media and left love to feature them as if theyre a huge threat from the right.

One way theyve set about accomplishing thisis through use of the term alt-right. They use it to lump white supremacists in with some regular conservatives who are dissatisfied with the mainstream Republican establishment. Its a brilliant tactic, since the two are not similar, but it makes people start to think they must be.

The reality is many white supremacists are on the left. The National Socialist Party, which callsitself the largest and most active National Socialist party in America, has plentyof views on the left.

The right denounces white supremacists and kicks them out of their events. There is no overlapping. And this is nothing new. Back in the 1960s, William F. Buckley Jr., editor of National Review, ensured that racists were not allowed in the conservative movement. As one of his biographers wrote, Buckley stood guard over the movement he founded and in what he called his greatest achievement kept it free where he could of extremists, bigots, kooks, anti-Semites and racists. In 1993, Buckley fired Joseph Sobran over a series of columns he considered antisemitic. Buckley and National Reviewdefined the essence of conservatism for multiple decades, so this was nothing to be dismissed.

Adam Bhala Lough recently wrote and directed a documentary currently popular on Netflix entitled Alt-Right: Age of Rage. But the only people on the right it features are white supremacists (some may call themselves white nationalists or other variations). There are no white supremacists on the left. The ones featured are shown saying vile things followed by conservative viewpoints; its very cleverly done, as if white supremacist and right wing are interchangeable. One headline states, Right-wing e-zine calls for black genocide. Racist images are posted in a row followed by Breitbart logos.

The left is represented by Daryle Lamont Jenkins, a charismatic black man who is a member of Antifa. Now that already raises red flags, because Antifa is almost completely white. So theyre trying to portray the violent hate group Antifa as a likable black man. They show him criticizing racism repeatedly and posing next to paintings of civil rights leaders. He brings up his military background, saying he took an oath to defend against foreign and domestic enemies. But both the right and the left find this admirable.

Antifas violent tactics are mostly ignored, except when one punches one of the worst white supremacists in the face, Richard Spencer. He is the main white supremacist featured and interviewed, a truly vile human being who is probably the most well-known since he craves attention. He says horrible things about Jenkins, like claiming he weighs at least 400 pounds and is gross looking. When he runs into him, he tells him he thought he would be dead by now because of obesity. To tie him to conservatives, Spencer is pictured standing in front of the Jefferson Memorial, then giving a speech where he yells Hail Trump! He denounces multiculturalism.

What the documentary wont tell you is that Spencer was kicked outof CPAC, the leading annual national conservative conference, in 2017 when he tried to show up. CPAC spokesman Ian Walters said Spencer wasnt a conservative, "He's anti-free markets, anti-Constitution, anti-pluralism."

Jenkins helpfully lumps Spencer in with the right by referring to Spencer as a right-wing propagandist, which is the same phrase someone on the left might use to label anyone on the right. Jenkins blames President Trump for giving them their juice. He uses Trump supporters interchangeably with white supremacists. The late Andrew Breitbart, a leading figure in the conservative movement during this century, is shown yelling at Jenkins to get out of his face, but tellingly the documentary doesnt reveal why. Breitbart was Jewish and hates racists. Jenkins says he goes after the National Socialist movement but there is no admission that the group is more on the left.

Another white supremacist the documentary prominently features and interviews is Jared Taylor, the founder of the racist site American Renaissance. Superficially, he looks like a traditional statesmanlike conservative and uses a tone of voice that sounds like it could be any thoughtful person on the right except vile things come out. He decries the people who criticize him in patriotic terms, saying Were the land of the free and the home of the brave. It is no coincidence he was chosen for this documentary. He puts on an annual conference of white supremacists every year, and complains that because of the efforts against him, they had only 300 show up instead of 400-450. Yep, thats how many in the entire U.S. would show up. Protesters show up outside his conferences. Tellingly, they are practically all white most black people realize his group is just a handful of losers who no one pays attention to except the media.

Mark Potok of the Southern Poverty Law Center chimes in periodically to reinforce the connection. He says that Dylann Roof, who shot and murdered people in a black church, was influenced by the radical right, a term commonly used for regular conservatives. He says there has been a rise in racist groups which might seem believable if youre now lumping in regular conservatives. Nowhere is it revealed that the SPLC is itself a hate group, labeling regular Christian organizations as hate groups. Its great to hear Potok denounce white supremacy but thats something we all agree on except a handful of white supremacists. Someone knowledgeable on the right could easily have sat in his place and said the same things.

The documentary covers the deadly Charlottesville riots of 2017. That event played right into their hand, because its organizer, Jason Kessler, a known white supremacist, named the rally Unite the Right as if he was including regular people on the right too. Its not very likely there were regular people on the right there, because one of the speakers saidthe rally was meant to unify various white nationalist factions against unidentified enemies. But the title even fooled President Trump, who denounced the violence but said there were "very fine people on both sides. Taylor helpfully stated that Trump appeals to those who are racially conscious. Even if true, as Ive explainedpreviously, this is no reflection on Trump.

People on the left are shown saying in interviews that they denounce violence by their side, while the white supremacists are shown saying its necessary. Jenkins says violence should only be engaged in as a form of defense, but we all know thats not representative of Antifa.

The problem is conservatives dont understand whats happening to us. They blindly accept the clever lumping in of white supremacists with regular conservatism and accept the phrase alt-right. I dont know anyone personally who refers to themself as the alt-right. Why dont conservatives create a documentary about the leftists in the National Socialist Party, the white supremacists who supportedHillary Clinton andBarack Obama as well as the antisemites in the Democratic Party vs. the conservatives who fight that racism? Perhaps feature the group Patriot Prayer, which is run by minorities and finds itself frequently the victim of Antifa, and gay Asian reporter Andy Ngo who covers these protests and was savagely beaten by Antifa. Maybe call it Alt-left and contact me to help fundraise.

Original post:

The Lefts Brilliantly Deceptive Documentary Alt-Right ...

Researchers Explain the Origins of Stony-Iron Meteorites – HeritageDaily

Pallasites are stony-iron meteorites, and are known for their unusual, visually attractive structures. However, to date, their origins have been hotly disputed.

Researchers at the Bavarian Research Institute of Experimental Geochemistry & Geophysics (BGI) of the University of Bayreuth have now succeeded in simulating the formation of all known types of pallasites by means of high-pressure experiments, and in placing them in the history of the solar system. They have been working closely with scientists from the Technical University of Munich and the Royal Holloway University of London. The new findings are presented in the journal Earth and Planetary Science Letters.

As the researchers have now discovered, pallasites arose from asteroid collisions that occurred approximately 4.5 billion years ago. In these collisions, iron from the smaller asteroid mixed with the olivine-rich material in the mantle of the larger asteroid. Billions of years later, quantities of this material mixture were blasted out of the surface of the asteroid by the force of another impact, and catapulted into space. Some of them finally hit the Earth. This genesis explains the unusual structures found in pallasites: They contain greenish brown olivine crystals surrounded by nickel and iron metal.

In research, the spatial arrangement of different materials in a rock and the resulting structures make up what is called texture. The pallasites that have been found and studied on Earth so far show a very large variety of textures. With our research work, we were able for the first time to reproduce in the laboratory all of the textures observed in pallasites.

This shows in an exemplary way how these meteorites can provide us revealing and unexpected insights into the early history of our solar system. To this end, we wish to continue our structural and chemical investigations of pallasite meteorites at BGI especially in the geochemical laboratories soon to be established here, says Prof. Dr. Audrey Bouvier, Professor of Experimental Planetology at the University of Bayreuth.

The new findings are the result of experiments on two extremely powerful devices: the MAVO high-pressure press at the Bavarian Research Institute of Experimental Geochemistry & Geophysics, and the identical SAPHiR high-pressure press. This is currently being set up with the assistance of Prof. Dr. Hans Keppler from BGI at Forschungs-Neutronenquelle Heinz Maier-Leibnitz (Research Neutron Source Heinz Maier-Leibnitz) at the Technical University of Munich.

With these instruments we can simulate very realistically the processes that led to the formation of meteorites, asteroids, or the planets. In order to be able to explain the formation of pallasites by asteroid collisions, we imitated the pressure and temperature conditions prevailing during these processes. Thus, we subjected samples containing iron and olivine to a pressure of one gigapascal (GPa) at 1,300 degrees Celsius. We then compared the changes in shape and internal stresses that we observed in the experimental samples with the textures found in the pallasite meteorites, explains Danielle Silva Souza, a Masters student from Bayreuth. After her bachelors degree in geosciences at the Federal University of Ouro Preto in Brazil, she came to Upper Franconia to work on experimental geoscience projects, which included the geochemical and experimental research project on pallasites. BGI offers excellent conditions for this research work, says the up-and-coming Bayreuth researcher.

University of Bayreuth

Header Image Texture of a pallasite: The brown and golden-brown areas contain olivines which are embedded in iron-nickel metal. Width: 3.5 cm. Image Credit : Audrey Bouvier

See the rest here:

Researchers Explain the Origins of Stony-Iron Meteorites - HeritageDaily

New 3D model reveals Venus’ volcanoes are actually still active – TNW

Across the lansdcape, steam vents hiss gaseous breath from deep inside the planet, creating an environment that feels like it hangs in the balance between our world and another. Stefanie Payne, A Year in the National Parks: The Greatest American Road Trip

The team designed models of geological activity beneath the surface of Venus. These 3D models of showed the formation of coronae formation identified features that could only be produced by recent volcanic activity on the surface of Venus. This finding provides the first evidence that the surface of Venus is still active, betraying active geology beneath the crust.

I focus on the lithosphere and surface geology, which is relatively accessible to planetary missions data. I like to call this kind of work comparative planetology. Venus is of special interest because of its gross similarity to the Earth. Yet the geology we observe is very different from that of the Earth. It has volcanoes and faults, yes, but they are organized very differently from the Earth. It does not have global tectonics like we do (at least at present day), Montsi tells The Cosmic Companion.

Without plate tectonics, movement of hot material through the planetary surface is the dominant force driving geological change on Venus today.

In the video above, you can take look at the planned EnVision mission to Venus, scheduled for launch in 2032. (Video credit: Thomas Widemann)

The surface of Venus was likely reworked on a large scale by volcanoes between 500 and 300 million years ago. Eruptions there have some similarities, as well as some differences to geological activity here on Earth.

Volcanoes on Venus actually look a lot like those on Earth: they have similar slope, activity on the summit etc. However, there are many regions of Venus that are covered with lava flows without necessarily a clear source. We see that in a few places on Earth, in regions called flood basalt provinces or traps. In our study we focused on very unusual structures called coronae, which do not have a good equivalent in terrestrial geology. They have a ring of faults and lava flow, and their interior can be quite complex, maybe have volcanic edifices, but these are not very well documented yet, Montsi describes.

This finding could assist teams heading future missions to Venus, including Europes EnVision mission, scheduled for launch in 2032.

This article was originally published on The Cosmic Companion by James Maynard, founder and publisher of The Cosmic Companion. He is a New England native turned desert rat in Tucson, where he lives with his lovely wife, Nicole, and Max the Cat. You can read this original piece here.

Astronomy News with The Cosmic Companion is also available as a weekly podcast, carried on all major podcast providers. Tune in every Tuesday for updates on the latest astronomy news, and interviews with astronomers and other researchers working to uncover the nature of the Universe.

See the rest here:

New 3D model reveals Venus' volcanoes are actually still active - TNW

Global Genetic Engineering Vector Market Analysis Recent Trends And Regional Growth Forecast By Types And Applications 2020 – Bulletin Line

Global Genetic Engineering Vector Market Research Report Covers the existing situation and the development predictions of the industry for 2020. This Report has been prepared primarily based mostly on particular market assessment with inputs from industry experts. This estimated report consists of all have observed element about marketplace evaluation, increase Demand and forecast analysis in all over the world. This record gives a few edged examine and solution within the complicated international of polymer-based totally thermal interface materials market.

Key Players:- Company A And More

Genetic Engineering Vector market report describes the growth of the industry by upstream & downstream, the industry overall and development, key companies, as well as type segment & application and so on, and makes a scientific prediction for the development industry forecasts based on an analysis.

Get Sample Copy Of Report From Here and Get Instant 10% Discount : https://www.eonmarketresearch.com/sample/72606

Genetic Engineering Vector Market research report quantifies opportunities and Challenges to prioritize with the revenue. Then report explains each component thoroughly like business Strategies, Industry trends, Regional Development, Performance matrix. This vital data about Genetic Engineering Vector industry will help to improve market growth in terms of manufacturing capacity, Sales during the Forecast period of 2020.

Genetic Engineering Vector Market regional analysis covers the following regions: North America, Europe, Asia-Pacific, South America, Middle East & Africa.

The scope of the Report: This report focuses on the Genetic Engineering Vector in the global market, especially in Europe, North America, and Asia-Pacific, Middle East, and Africa, South America. This report describes the market based on regions, type, manufacturers, and application.

Buy This Premium Report: https://www.eonmarketresearch.com/buy/72606

Market Segment On The Basis Of Product Type Includes:-

General Type

Applications Mentioned In This Report:-

In Vitro StudiesClinical

The report then estimates 2020 market development trends of Genetic Engineering Vector market. Outline of upstream raw materials, downstream trade and prevailing market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Genetic Engineering Vector market before evaluating its feasibility.

This report presents an extensive analysis of the current Genetic Engineering Vector trends and emerging estimations & dynamics of the global Genetic Engineering Vector industry. Likewise, explains the comprehensive analysis of factors that drive and restrict the growth of the Genetic Engineering Vector market. Further covers a detailed analysis of the Genetic Engineering Vector industry based on type and application help in understanding the Genetic Engineering Vector trending products across geographies. Then highlights the potency of buyers and suppliers to understand the Genetic Engineering Vector market potency. Finally, an extensive analysis of the Genetic Engineering Vector market is conducted by key product positioning and monitoring of top players within the Genetic Engineering Vector market framework.

Place An Inquiry Before Investment @ https://www.eonmarketresearch.com/enquiry/72606

Table of Contents

1. Industry Overview of Genetic Engineering Vector2. Global Genetic Engineering Vector Competition Analysis by Players3. Company Profiles4. Global Genetic Engineering Vector Market Size by Type and Application (2020-2025)5. United States Genetic Engineering Vector Development Status and Outlook6. EU Genetic Engineering VectorDevelopment Status and Outlook7. Japan Genetic Engineering Vector Development Status and Outlook8. China Genetic Engineering Vector Development Status and Outlook9. India Genetic Engineering Vector Development Status and Outlook10. Southeast Asia Genetic Engineering Vector Development Status and Outlook11. Market Forecast by Regions, Type, and Application (2020-2025)12. Genetic Engineering Vector Market Dynamics13. Market Effect Factors Analysis14. Research Finding/Conclusion15. Appendix

**Thanks for reading this article; you can also get individual chapter wise section or region wise report version like United States, Europe, Middle East, and Africa or Asia-Pacific.**

About Us:

Eon Market Research (EMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers.

Contact Us:

Eon Market ResearchPhone: +1 703 879 7090Email: [emailprotected]

Read the original:

Global Genetic Engineering Vector Market Analysis Recent Trends And Regional Growth Forecast By Types And Applications 2020 - Bulletin Line

Allow field trials of Bt brinjal to ensure safety of crops, agri-tech body writes to govt – ThePrint

Text Size:A- A+

New Delhi: The Alliance for Agri Innovation (AAI), a leading agri-tech industry body, has written to the central government and various states to allow field trials of Bt brinjal, a genetically-modified (GM) crop that was banned in 2010 following concerns raised about public health and biodiversity.

In a statement released Friday, the AAI said field trial was the only way to ensure safety of crops. blocking such trials amounts to blocking national development, it said.

AAIs letter has been sent to the agriculture ministry and chief ministers of Madhya Pradesh, Karnataka, Bihar, Chhattisgarh, Jharkhand, Tamil Nadu, Odisha and West Bengal.

The AAI statement also mentions how a 2019 peer-reviewed study had found that net returns to farmers from Bt brinjal crop averaged $2151/ha (Rs 1.61 lakh/ha) compared to $357/ha (Rs 26,768/ha) from non-Bt brinjal crop.

In India, Bt brinjal was cleared for commercial cultivation by the Genetic Engineering Appraisal Committee (GEAC) in 2009 but it was placed under an indefinite moratorium the following year by then minister of state for environment, Jairam Ramesh.

Several farmers from various states, including Maharashtra and Haryana, were found to be openly flouting the GM crop ban last year and sow Bt brinjal.

The crop has been commercially grown in Bangladesh since 2014 the first South Asian country to do so.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrints future.

SUBSCRIBE NOW

Also read: Why farmers are still having to protest for their right to sow GM seeds, even in a pandemic

Brinjal is an extremely pest-prone crop, and highly susceptible to the fruit and shoot borer (FSB) pest.

To reduce loss of yield, farmers often end up spraying this crop multiple times. A report from Bangladesh had earlier noted that protein in Bt brinjaldisrupts the digestive systems of certain pests, causing them to die within three days of ingestion.

It had also stated that advantages of using Bt brinjal over non-Bt brinjal were lower pest infection, higher yields, 56 per cent reduction in environmental toxicity and fewer complaints about symptoms consistent with pesticide exposure.

Ram Kaundinya, director general of AAI, said in the statement, The deadly FSB is a menace for farmers and its caterpillar also finds its way into our homes through infected brinjals. By controlling this with Bt technology, we can save farmers income, reduce pesticide load on the environment and provide pesticide- and insect-free brinjals to consumers.

AAI head Paresh Verma added, Development of indigenous technology is in line with the Atmanirbhar Bharat mission launched by Prime Minister Narendra Modi. Delays due to a paralysis in the decision-making process by the central and state governments have essentially stalled the progress in research to develop new technologies.

The AAI statement also noted how several studies and analyses into GM cultivation over the past 23 years have found no evidence of adverse health effects on humans or animals.

Also read: Now, Bangladesh set to steal march over India with GM rice that fights malnutrition

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the medias economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the countrys most robust editing and fact-checking team, finest news photographers and video professionals. We are building Indias most ambitious and energetic news platform. And we arent even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrints future. It will take just a few seconds of your time.

Support Our Journalism

See the original post:

Allow field trials of Bt brinjal to ensure safety of crops, agri-tech body writes to govt - ThePrint

What to Watch When Twist Bioscience Reports Fiscal Q3 Results – Motley Fool

Uncertainty is one of the central themes of investing in 2020, but investors can be certain of one thing: Valuing shares of Twist Bioscience (NASDAQ:TWST) at more than 30 times sales is a little bit ridiculous.

The company's technology platform is intriguing, but it hasn't shown signs of becoming a commercial success from a business standpoint. In fact, Twist Bioscience has reported growing losses as it has scaled its business and relied on equity financing to fund operations. That hasn't stopped the small-cap stock from soaring by more than 200% since the beginning of 2020.

On the one hand, Twist Bioscience is uniquely positioned to help customers respond to the coronavirus pandemic. It has also signed a flurry of drug discovery deals this year. On the other hand, the financial impacts of those catalysts are a bit fuzzy. Here's what metrics investors will be watching when the company reports fiscal third-quarter 2020 operating results.

Image source: Getty Images.

Twist Bioscience is developing a DNA synthesis technology platform that can be used in drug discovery, genetic engineering experiments, and diagnostic panels. It's not necessarily the technological endgame, but it's the best we have right now. Heck, the company supplies many of its competitors with synthetic DNA.

And its technology platform looks to be playing an important role in the global response to the coronavirus pandemic. Twist Bioscience has created synthetic controls of the SARS-CoV-2 virus that can be used in diagnostic tests to detect whether a person is currently infected, launched SARS-CoV-2 antibody panels for research activities, and inked drug discovery deals with biopharmaceutical companies developing therapeutic antibodies to treat COVID-19.

Additionally, the company doesn't appear to have slowed future-oriented investments in its technology platform and businesses. Twist Bioscience has signed non-COVID-19 drug discovery deals with Takeda Pharmaceuticals, Seismic Bio, and Invetx (an animal health start-up) since the end of the fiscal second quarter of 2020.

The biggest question facing investors is pretty simple: Will announcements translate into tangible progress?

Investors are assuming Twist Bioscience will report a noticeable bump in quarterly revenue from coronavirus-oriented research tools, although financial details weren't disclosed for any of the drug discovery deals. The latter appear to be dependent on technology access fees and milestone or royalty payments, which wouldn't necessarily have a significant near-term impact.

Here's the problem: Even an incredible quarter probably isn't enough to make sense of the stock's current valuation. Investors shouldn't be paying 30 times sales for a money-losing business that has grown operating losses faster than gross profit and is entirely reliant on stock offerings to keep the lights on.

In other words, even a relatively strong quarter could cause the stock to drop. There's simply too much success baked into the company's market valuation right now. It's difficult to see how Twist Bioscience's $3 billion valuation is sustainable with publicly available information. Then again, it's 2020. Many stock valuations don't make much sense right now.

A great business is always a great investment in the long run, but a great investment is not always a great business. Thus far in 2020, Twist Bioscience has been a great investment, but the stock's ascension is detached from business fundamentals. That's likely to be true even with an amazing increase in revenue from the coronavirus pandemic, assuming that's what the results show. Investors might want to take that into account, as starting or adding to a position at current prices might sap long-term returns. Unless the company announces a major event that's not currently on investors' radar, it's simply difficult to see shares holding onto recent gains.

Here is the original post:

What to Watch When Twist Bioscience Reports Fiscal Q3 Results - Motley Fool

Viewpoint: Battling deadly disease with gene drives is worth the limited risk – Genetic Literacy Project

The fate of society rests in part on how humans navigate their complicated relationship with insects trying to save good insects and control bad ones. Some insects, like mosquitoes, bite people and make them sick remember Zika? Now the U.S. mosquito season is already in full swing, withover 10 cases of Dengue feverreported in the Florida Keys this year. Some insects, likebees, are pollinatorsthat help produce our food. Others, likelocusts, currently threaten cropsin East AfricaandAsia, preferring to eat our food instead.

Insects have proven themselves extremely capable at evolving strategies to get around control methods, such as chemical insecticides and habitat modification, and current pest control technologies are simply not keeping up.

We arebothinsect scientists. Our research has includedengineering a fungus to control malaria mosquitoes,uncovering the reproductive biology of honey bee workersand understanding thehealth impacts of invasive ticks. Weve come to appreciate the potential of emerging technologies like gene drive. This technology can guarantee that a trait will be inherited by the next generation. Such traits include making mosquitoesimmune to the malaria parasiteso they cannot spread the disease to humans.

Recently we contributed to astatement that advocates for continuing gene drive research. In light ofcalls for a moratorium, this statement recognizes that a ban on gene drive research would hamper a better understanding, and thus mitigation, of risks associated with this technology.

Moratoriums on gene drive technology have been called for and rejectedat the last twoUnited Nations Conventions on Biological Diversity. But there isa new push for a moratorium.

Gene drive is a technology that could allow society to control insects in a more targeted manner.

The general underlying principle of all gene drives is an organism that will produce offspring similar to themselves.

Some characteristics are randomly passed on from parents to the next generation. However, gene drive forces a different type of inheritance that ensures a specific characteristic is always present in the next generation. Scientists engineer gene drive using various molecular tools.

Gene drive is not just a human invention; some occur naturally in insects. For example, instalk-eyed flies, a gene on a sex-related chromosome causes any male fly to die without a certain gene cargo, including a gene that results in longer eyestalks. This type of genetic phenomenon has been well studied by scientists.

To date, gene drive has been discussed in the media primarilyin order to eradicate malaria. This may give you the impression that gene drive can be used onlyto drive mosquitoes to extinction. However, gene drive technologies are highly versatile and can be designed to bring about different outcomes. They can also be applied in most insect species that scientists can study in the laboratory.

Insects reproduce quickly and produce lots of offspring, which makes them obvious candidates for a technology that relies on inheritance like gene drive. This is why insects are at the leading edge of gene drive research. Gene drive is a new technology that could provide a solution to a variety of insect issues society faces today.

For instance, a gene drive has beendeveloped to stop a major crop pest, the spotted-wing Drosophila. Insecticide sensitivity could be spread through populations of this pest species to stoptens of millions of dollars in crop damage every yearin the United States.

Gene drive could also be a more targeted approach to stopping invasive insects, such as the infamousfire ant, from destroying native ecosystems. In the United States, millions of dollars have been spent onremoving fire ants using techniques including chemical insecticides, but if these persistent ants are not completely eradicated, they invade again.

Aside from how good insects are at circumventing our strategies to control them, another major struggle for controlling insects is finding them. Insects have evolved to quickly find the opposite sex to mate, and gene drives, which are passed on by mating, can take advantage of this fact of insect life. This also means this technology targets only the intended species, which is not the case for chemical insecticides currently in use.

Insect scientists, inspired by natural examples of gene drive, have wanted to design gene drive in insects for decades. Only recently have new molecular tools, such as the gene editing toolCRISPR-Cas, made the gene drive dream a reality. For now, gene drive insectslive in laboratories and none has been released into the wild. Still, a lot can be learned about how gene drive works while it is safely contained in a laboratory.

Using gene drive is not a universally popular idea. Criticisms tend to fall into three categories: ethical concerns, mistrust of technology and unintended ecological consequences.

Ethical concerns about gene drive are often motivated by larger issues, such as how to stop gene drive from being used in biological weapons by engineering insects that are more dangerous. Then there is the question of who should decide which gene drive projects move forward and what types of insects with gene drive can be released into the environment. These questions cant be answered by scientists alone.

Societal mistrust of technologyis a hurdle that some powerful, innovative technologies must overcome for public acceptance. The issue of technological mistrust often stems from disagreements about who should be developing technology to control insects and for what purposes.

The third common argument against gene drive technologies is that they might cause unintended consequences in the ecosystem because gene drive is designed by humans and unnatural. What will happen to the natural ecosystem if a population, even of mosquitoes that make people sick, is driven to extinction? Will this cause threats to natural biodiversity and the security of food? These questions are ultimately asking the consequences of intervening in the natural order of the world. But who defines what is the natural state of an ecosystem?Ecosystems are already constantly in flux.

When a gene drive is developed, it is tailored to the needs of a particular situation. This means theanticipated risksposed by each gene drive are project-specific and should be considered and regulated on a case-by-case basis. A responsible way to protect society from these risks is to advocate for continued research that enables scientists to describe and find solutions to them. Beyond the science, regulatory and accountability systems are needed so that regulations are adhered to and public safety is protected.

Researchers are also still exploring the science underlying the gene drive. Can gene drive be designed to be reversible or more efficient? Can the effect of a gene drive on an ecosystem be predicted? Such important unanswered questions are why even the most ardent supporters of this technology say more research is needed. Society needs new tools to control insect pests and protect ecosystems, and gene drive promises to augment our toolbox.

Isobel Ronai is an Endeavour Postdoctoral Research Fellow at Columbia University. Follow her on Twitter @IsobelRonai

Brian Lovett is a postdoctoral researcher at the Division of Plant and Soil Sciences at West Virginia University working on fungal biology and biotechnology. Follow him on Twitter @lovettbr

This article was originally published at the Conversation and has been republished here with permission. Follow the Conversation on Twitter @ConversationUS

Read the original here:

Viewpoint: Battling deadly disease with gene drives is worth the limited risk - Genetic Literacy Project

22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020 – Stockhouse

Key Highlights:

WILLIAMSVILLE, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (22nd Century” or the Company”), a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding, today reported results for the second quarter ended June 30, 2020.

Despite the unprecedented challenges brought on by COVID-19, I am pleased to report net sales revenue of $6.4 million for the second quarter of 2020, up 11% from the prior year, continued gross profit margin expansion, and improved operating loss. These results demonstrate our ability to execute on our initiatives to improve our margins and cost structure. Our financial position remains strong and we will continue to operate with strict cost controls, allocate our resources efficiently, and deploy capital where we believe it will give us the greatest return on our investments,” said James A. Mish, Chief Executive Officer of 22nd Century Group.

With the comment period now closed on our Modified Risk Tobacco Product Application, the team is laser focused on setting the stage for a successful VLN® launch upon the authorization of our MRTP Application by the FDA. I am exceedingly proud of the dedication and tremendous progress the team has made so far this year and believe we are well positioned to capitalize on the many opportunities ahead,” Mish added.

Business Highlights and Notable Events:

COVID-19 Update

2020 Second Quarter and Year-to-Date Financial Results

Balance Sheet and Liquidity

Second Quarter Earnings Conference Call 22nd Century will host an audio-only webcast today at 8:00 a.m. ET to discuss the Company’s second quarter 2020 financial results.

The live audio webcast will be accessible in the Events section on the Company's Investor Relations website at http://www.xxiicentury.com/investors/events. An archived replay of the webcast will also be available shortly after the live event has concluded.

About 22nd Century Group, Inc. 22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing and modern plant breeding. The Company’s primary mission in tobacco is to reduce the harm caused by smoking by bringing its proprietary reduced nicotine content tobacco cigarettes containing 95% less nicotine than conventional cigarettes to adult smokers in the U.S. and international markets. The Company’s primary mission in hemp/cannabis is to develop proprietary hemp/cannabis plants with valuable cannabinoid profiles and agronomic traits and to commercialize those plants through a synergistic portfolio of strategic partnerships in the hemp/cannabis industry.

Learn more at xxiicentury.com, on Twitter @_xxiicentury and on LinkedIn.

Cautionary Note Regarding Forward Looking Statements This press release contains forward-looking statements concerning our business, operations and financial performance and condition as well as our plans, objectives and expectations for our business operations and financial performance and condition that are subject to risks and uncertainties. All statements other than statements of historical fact included in this press release are forward-looking statements. You can identify these statements by words such as aim,” anticipate,” assume,” believe,” could,” due,” estimate,” expect,” goal,” intend,” may,” objective,” plan,” potential,” positioned,” predict,” should,” target,” will,” would” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management's beliefs and assumptions. These statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All forward-looking statements are subject to risks and uncertainties and others that could cause actual results to differ materially from those contained in our forward-looking statements. Please refer to the Risk Factors” in our Annual Report on Form 10-K filed on March 11, 2020 and in our subsequently filed Quarterly Report on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law

Adjusted EBITDA, which the Company defines as earnings before interest, taxes, depreciation and amortization, as adjusted by the Company for certain non-cash and non-operating expenses, as well as certain one-time expenses, is a financial measure not prepared in accordance with generally accepted accounting principles (GAAP”). In order to calculate Adjusted EBITDA, the Company adjusts the net (loss) income for certain non-cash and non-operating income and expense items listed in the table above in order to measure the Company’s operating performance. The Company believes that Adjusted EBITDA is an important measure that supplements discussions and analysis of its operations and enhances an understanding of its operating performance. While management considers Adjusted EBITDA to be important, it should be considered in addition to, but not as a substitute for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating loss, net (loss) income and cash flows from operations. Adjusted EBITDA is susceptible to varying calculations and the Company’s measurement of Adjusted EBITDA may not be comparable to those of other companies.

Below is a table containing information relating to the Company’s Adjusted EBTIDA for the three and six months ended June 30, 2020 and 2019, including a reconciliation of net (loss) income to Adjusted EBTIDA for such periods.

Contacts: Mei Kuo 22nd Century Group (716) 300-1221 mkuo@xxiicentury.com

John Mills ICR (646) 277-1254 john.mills@icrinc.com

Deirdre Thomson ICR (646) 277-1283 deirdre.thomson@icrinc.com

See the original post:

22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020 - Stockhouse

NASAs Curiosity Rover Reaches an Impressive Milestone During its Mars Mission – Webby Feed

Home News NASAs Curiosity Rover Reaches an Impressive Milestone During its Mars Mission

The Curiosity rover was sent to Mars by NASA in 2012 in order to study the planets Gale Crater. The bigger goal was to find out if the crater could have supported life as it exists on Earth. Very few people suspected that Curiosity could go so far as it did. Life wasnt found on Mars until now, but Curiosity reached an unprecedented milestone.

Its time to say Happy Birthday! to the Curiosity rover that had been roaming the Martian surface for eight wonderful years.

NASAs Curiosity rover celebrated its 8th anniversary yesterday, on August 5. The rover didnt find any little green men living on the Red Planet, but it still had enormous contributions for making scientists understand the planet a lot better.

Judging by the data gathered by the Curiosity rover, scientists were able to conclude that the Gale crater from Mars hosted a potentially habitable lake-and-stream system. The rover also found some complex organic chemicals on Mars.

Space agencies are continuing to explore the Red Planet in order to find out all the possible dangers that astronauts could be facing there. NASA plans to send humans to the Moon after more than half a century, along with the Artemis program. If everything goes according to the plan, the next destination is Mars. Scientists hope to begin the terraforming of Mars in the future, but we are naive to think that well be able to move our luggage on the Red Planet in less than a hundred years. But for a short visit to Mars, that wouldnt be a problem with the current technology.

If the distance between Earth and the Moon is only 384,000 kilometers, well have to travel much more if we want to arrive to our neighboring planet. The shortest distance between our planet and Mars is 54.6 million kilometers.

Related

More here:

NASAs Curiosity Rover Reaches an Impressive Milestone During its Mars Mission - Webby Feed

Regulatory Focus, July issue: Cell and gene therapy – Regulatory Focus

Feature articles during July focused on global regulatory strategy for cell and gene therapy, with articles on US and EU regulations and guidances and the development and manufacture of the therapies. Also included were articles on recasting the corrective and preventive action (CAPA) process as a continuous improvement process, a military-civilian perspective on real-world evidence (RWE) to support regulatory decision making, and regulatory reporting in multinational trials during COVID-19.Advanced therapy medicinal products (ATMPs), including cell therapies, gene therapies, and tissue-engineered products, are highly complex treatments that differ from traditional medicines, both in how they are made and administered and in the benefits they may provide. Regulations for these products were established relatively recently and are still evolving in many jurisdictions globally. The novelty of these products, the inherent complexities of cell and gene therapy products, and the lack of experience with such products pose many challenges for developers.In part one of this two-part series, this months expert authors address these challenges and offer hands-on, practical advice and guidance on regulation and production of ATMPs. If there is one clear, take-home message to developers, it is that early and frequent collaboration with regulatory agencies, during both the approval and development phases, is paramount. It saves time and money, and it reduces the risk of a negative impact on the trajectory of a clinical trial. Part 2 of the series will cover upstream manufacturing and process controls for biologics, the ATMP regulatory landscape in China, EU GMP requirements for autologous cell therapies and parenteral biologics, and regulatory challenges and opportunities in the US.Regulations and guidancesThe regenerative medicine advanced therapy (RMAT) field has the potential to provide profound benefits to patients with serious diseases and disorders, and the RMAT designation is helping drive these transformative technologies to market. In Update on RMAT designations, William K. Sietsema and Janet Lynch Lambert discuss the scope and purpose of the special designation for RMATs created by the passage of the 21st Century Cures Act and provide a tally of products that have received the special designation to date. However, while the promise of regenerative medicines to cure disease is propelling the field at a rapid pace, developing these therapies requires a rigorous, carefully planned approach to ensure a seamless progression to regulatory approval and commercial success.Siegfried Schmitt expands on that point about carefully navigating the complex and nuanced regulatory environment in two articles on US and EU regulations for RMATs and ATMPs, respectively. In US regulations for regenerative medicine advanced therapies, he provides a user-friendly, quick-access list of RMAT-related regulations and guidances. The article includes a useful introduction to the application process and descriptions of the features and criteria for various expedited program options, including breakthrough therapy, fast track, advanced approval, and priority review.In Regulation of advanced therapy medicinal products in the EU, Schmitt explains some of the terminology relating to ATMPs before documenting the key EU regulations and guidances for each therapy type. He concludes with discussions on marketing authorization, accelerated regulatory pathways, and market access. Again, he urges companies and developers to engage with the regulatory agencies early and often throughout the approval process and to seek external regulatory support, especially if the developer has limited in-house regulatory resources.Development pathways and manufacturingTwo articles shift the focus from the regulatory landscape to development and manufacturing pathways. The drug manufacturing facility environment presents one of the major sources of potential contaminants in the final biologic drug product, so it is critical to design facilities with cleanroom environmental controls and monitoring that adhere to the highest standards of current good manufacturing practice (cGMP) quality guidelines, write Mo Heidaran and colleagues. In Designing a biologics manufacturing facility: Early planning for success, the authors lay out the planning steps for compliance with cGMP to readiness for chemistry, manufacturing, and controls (CMC). The authors warn that the pressure to reduce time to market put considerable stress on all aspects of commercial operations and commercial-scale manufacturing development, so yet again, early tactical and strategic planning essential.In Advanced therapies: Trip hazards along the development pathway, Kirsten Messmer and Richard Dennett focus on the challenges and complexities of ferrying advanced therapies along the developmental pathway, which they call the trip. They examine the importance of some of the fundamental building blocks for the development program and highlight some commonly encountered challenges, or trip hazards, for cell and gene therapies. The suggest developers establish sound technical and regulatory strategies to better anticipate and avoid the trip hazards, which could prove costly, both in time and money, and have a negative impact the overall clinical study program.CAPA, RWE, and COVID-19Todays CAPA process has become highly focused on compliance, which has manufacturers struggling to determine which issues require a structured CAPA process and which can be resolved in alternative ways, writes Kathryn Merrill in Recasting CAPA as a continuous improvement process. Merrill summarizes a white paper developed by the Medical Device Innovation Consortium, in which the CAPA process is recast as a continuous improvement process for driving higher product quality and improved patient safety. It is intended to enable organizations make a greater number of improvements more quickly, and over time, which will have a favorable impact on product quality in the field.During the Afghanistan and Iraq wars, the US Military Health System used an approach known as focused empiricism to develop new approaches for casualty care. In doing so, it implemented real-world data (RWD) and RWE into a system of performance improvement and product development to achieve historic rates of survival, write Todd E. Rasmussen, a colonel in the US Air force, and Brian J. Young. In A military-civilian perspective on real-world evidence to support regulatory decision making, the authors summarize the framework promoting the collection and analysis of RWD in the healthcare system and describe a new era of collaboration between the US Department of Defense and the FDA, within the context of a new Public Law 115-92, to coordinate on the delivery of military-relevant medical products. The article reviews the FDA evidentiary standards for medical product approval and gives examples of how RWE can help meet those standards.COVID-19 continues to disrupt and redefine the regulatory process and activity. In Managing uncertainty: Regulatory reporting in multinational trials during COVID-19, Ioana Ionita discusses regulatory reporting challenges for multinational clinical trials during the pandemic, as well as the challenge of assessing what is reportable and how to submit COVID-19 risk mitigation measures. She offers real-world experience on how she and her colleagues stopped and restarted recruitment in ongoing multinational clinical trials, and how those actions were reported globally. Ionita concludes that close collaboration between sponsors, CROs, local affiliates, investigational sites, and health authorities is important in choosing strategies under challenging circumstances and when no precedent applies.Whats coming in August?Articles during August will focus on global clinical trials and clinical trial applications. Despite ICH efforts to produce guidelines for the development of drugs and biologics and to standardize the format of marketing applications, there remain considerable differences among countries in the format of clinical trial applications and health authority review processes. This collection of articles will address these divergent formats and processes and provide options for navigating the regulatory aspects of clinical trials. Look for these topics and more throughout August at http://www.raps.org.October call for articlesFor October, Regulatory Focus will look at the regulatory toolboxthe tools regulatory professionals need and where to find them, with an emphasis on websites, guidances, meeting minutes and FDA correspondence, including warning letters, enforcement actions, 483s, and notices. Articles will discuss how to interpret the meaning behind regulatory agency actions and available options for documentation. The submission deadline for articles is 1 September 2020. To contribute to the October issue or suggest a topic, contact Rene Matthews at rmatthews@raps.org.Citation Matthews R. Regulatory Focus, July issue: Cell and gene therapy. Regulatory Focus. July 2020. Regulatory Affairs Professionals Society.

More here:

Regulatory Focus, July issue: Cell and gene therapy - Regulatory Focus

G-CON PODs Selected for Expression Therapeutics’ Gene Therapy Manufacturing Facility – PR Web

Photo courtesy of Expression Therapeutics

COLLEGE STATION, Texas (PRWEB) August 05, 2020

G-CON Manufacturing, the leader in prefabricated, flexible cleanroom solutions, announced today that it has been selected by Expression Therapeutics to support its cleanroom build-out at its new clinical manufacturing facility in Cincinnati, Ohio. The PODs will provide the cleanroom infrastructure for the production of Expression Therapeutics cell and gene therapies.

For this project, time was a critical factor for Expression Therapeutics. Offsite manufacturing of the cleanroom infrastructure allowed for concurrent preparation of their new host facility, significantly reducing the projects overall timeline. Future expandability was also key, as their POD system is being designed to accommodate Expression Therapeutics cleanroom needs for its next phase. Removable panels incorporated into the POD walls will easily allow integration of additional POD clean space. Since PODs are autonomous and completely assembled offsite, this expansion will result in minimal downtime and disruption to the functioning first phase POD cleanrooms.

Its great to work in an industry where innovation moves so fast and helps people live better lives, said Tim Rasmussen, Sales Engineer at G-CON Manufacturing. Companies like Expression Therapeutics need infrastructure to develop breakthrough therapies, and they need them fast. We are proud to play a part in making patients lives better by delivering state of the art cleanroom solutions more quickly than any other solution on the market.

We decided to utilize advanced pre-built modular cleanrooms from G-CON to accelerate our buildout and commence vector manufacturing this year. With vector GMP manufacturing backlogs today typically exceeding 18 months, we wanted to bring on additional capacity as soon as possible to serve clients said Bill Swaney, Vice President of Manufacturing for Expression Therapeutics.

About G-CON ManufacturingG-CON Manufacturing designs, builds and installs prefabricated G-CON POD cleanrooms. G-CONs POD portfolio provides cleanrooms in a number of dimensions for a variety of uses, from laboratory environments to personalized medicine and production process platforms. G-CON POD cleanroom units surpass traditional cleanroom structures in scalability, mobility and the possibility of repurposing the PODs once the production process reaches its lifecycle end. For more information, please visit G-CONs website at http://www.gconbio.com.

G-CON Manufacturing... BUILDING FOR LIFE

About Expression TherapeuticsExpression Therapeutics is a biotechnology company based in Atlanta and Cincinnati. The current therapeutic pipeline includes advanced gene therapies for hemophilia, neuroblastoma, T-cell leukemia/lymphoma, acute myeloid leukemia (AML), and primary immunodeficiencies such as hemophagocytic lymphohistiocytosis (HLH).

Share article on social media or email:

See the rest here:

G-CON PODs Selected for Expression Therapeutics' Gene Therapy Manufacturing Facility - PR Web

CRISPR co-discoverer on the gene editor’s pandemic push – Axios

The coronavirus pandemic is accelerating the development of CRISPR-based tests for detecting disease and highlighting how gene-editing tools might one day fight pandemics, one of its discoverers, Jennifer Doudna, tells Axios.

Why it matters: Testing shortages and backlogs underscore a need for improved mass testing for COVID-19. Diagnostic tests based on CRISPR which Doudna and colleagues identified in 2012, ushering in the "CRISPR revolution" in genome editing are being developed for dengue, Zika and other diseases, but a global pandemic is a proving ground for these tools that hold promise for speed and lower costs.

Driving the news: Last week, the NIH awarded $250 million for the development of COVID-19 diagnostic tests to a handful of companies, including Mammoth Biosciences, which is working on a CRISPR-based test that CEO Trevor Martin says will deliver 200 tests per hour per machine.

The challenge now is "getting it into a format where it can be used easily either in a laboratory or at the point-of-care," like the doctor's office or home, she says.

How it works: Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR, are sequences of genetic code that bacteria naturally use to find and destroy viruses.

That editing ability is viewed as having vast potential for treating disease, a nascent use of CRISPR.

But there's a persistent problem: Getting the sizable CRISPR system through the membranes and to the DNA of the cells that need editing.

And, there are other concerns about off-target editing with currently available enzymes and unknown long-term effects of gene editing directly in the body.

The intrigue: CRISPR could one day be wielded in future pandemics.

Yes, but: That would require sophisticated understanding of how a virus changes and the immune system's complex response to it.

The big picture: Such "genetic vaccination" is a long way off, but it could eliminate having to wait until a virus shows up, make a vaccine to that virus and then vaccinate people, she says.

See the original post:

CRISPR co-discoverer on the gene editor's pandemic push - Axios

Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations – GlobeNewswire

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie. Voyager retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations.

Our efforts to harness AAV-based gene therapy to produce antibodies directly in the brain and overcome major limitations with delivery of current biologics across the blood-brain barrier have been highly productive, said Omar Khwaja, M.D., Ph.D., Chief Medical Officer and Head of R&D at Voyager. Through the tau and alpha-synuclein collaborations, we believe we have made considerable progress against targets for neurodegenerative diseases with this novel approach, reinforcing our enthusiasm for its potential to deliver therapeutically efficacious levels of biologics to the brain and central nervous system. We believe our continued work on discovery and design of novel AAV capsids with substantially improved blood-brain barrier penetrance will also considerably broaden the potential of AAV-based gene therapy, including vectorized antibodies or other biologics, for the treatment of severe neurological diseases.

The tau and alpha-synuclein research collaborations were formed in 2018 and 2019, respectively. Under the terms of the collaboration agreements, Voyager received upfront payments to perform research and preclinical development of vectorized antibodies directed against tau and alpha-synuclein. With the conclusion of the collaborations, Voyager has regained full clinical development and commercialization rights to certain product candidates developed within the context of the collaboration for the tau program. Voyager is free to pursue vectorized antibody programs for tau and alpha-synuclein alone or in collaboration with another partner.

Voyager does not anticipate any changes to its cash runway guidance due to the termination of the agreements. As of March 31, 2020, the Company had cash, cash equivalents and marketable debt securities of $250.9 million, which, along with amounts expected to be received for reimbursement of development costs from Neurocrine Biosciences, is expected to be sufficient to meet Voyagers projected operating expenses and capital expenditure requirements into mid-2022.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyagers wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinsons disease, Huntingtons disease, Friedreichs ataxia, and other severe neurological diseases. For more information, please visit http://www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as may, might, will, would, should, expect, plan, anticipate, believe, estimate, undoubtedly, project, intend, future, potential, or continue, and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding the ability of Voyager to maintain research and development activities currently included within the collaboration agreements with AbbVie; Voyagers ability to advance its AAV-based gene therapies and its ability to continue to develop its gene therapy platform; the scope of the intellectual property rights and other rights that will be available to Voyager following the termination of the AbbVie collaboration agreements; the anticipated effects of the termination of the AbbVie collaboration agreements on Voyagers anticipated financial results, including Voyagers available cash, cash equivalents and marketable debt securities; and Voyagers ability to fund its operating expenses with its current cash, cash equivalents and marketable debt securities through a stated time period are forward looking. All forward-looking statements are based on estimates and assumptions by Voyagers management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the continued cooperation of AbbVie in activities arising from the termination of the AbbVie collaboration agreements, the development of the gene therapy platform; Voyagers scientific approach and general development progress; Voyagers ability to create and protect its intellectual property; and the sufficiency of Voyagers cash resources. These statements are also subject to a number of material risks and uncertainties that are described in Voyagers most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investors:Paul CoxVP, Investor Relations857-201-3463pcox@vygr.com

Media:Sheryl SeapyW2Opure949-903-4750sseapy@purecommunications.com

See more here:

Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations - GlobeNewswire

And they’re off! Campaign signs popping up – Las Cruces Bulletin

By Mike Cook

As of Aug. 7, there are 88 days until the Tuesday, Nov. 3, General Election. Yard signs and billboards are allowed 90 days before an election, and they have already begun to appear.

There are 28 federal, statewide and local races on Doa Ana County ballots, including 59 candidates: 28 Democrats, 25 Republicans, four Libertarians, one Constitution Party candidate and one declined-to-state (DTS) candidate. There are eight incumbent local district judges and one state Supreme Court justice up for voter retention.

There also will be five ballot initiatives for voters to consider: two constitutional amendments and three statewide bond issues that would allocate $200 million for senior centers, libraries, colleges and universities across the state.

Because state legislators and county commissioners are elected by districts, not everyone will see the same names on their ballots. Voters will choose from the same group of candidates for president, U.S. Senate and U.S. House New Mexico district two, county clerk and treasurer and Third Judicial District attorney, and will vote up or down for statewide and local judicial retentions.

But depending on where they live, voters will see different candidates in the six state Senate and eight state House of Representatives races that include Doa Ana County. Three of five county commission seats are also on this years ballot. The other two commission seats along with the county sheriff, assessor and probate judge will be up in 2022.

Democrats are unopposed in one statewide and two local races: Court of Appeals position three, district attorney and county commission district two. Gerald Byers, who also had no primary opponent, will succeed Mark DAntonio, who is retiring after two four-year terms, as district attorney.

Anthony Mayor Diane Murillo-Trujillo defeated incumbent Ramon Gonzalez in the June county commission district two Primary and will become a member of the commission next January.

The four Libertarian candidates are running for president, U.S. Senate, U.S. House, Court of Appeals position two (a write-in candidate whose status is being evaluated by the New Mexico Secretary of States office) and county commission district four.

The lone Constitution Party candidate is running for president and the only DTS candidate is running for U.S. House district two.

There are 22 incumbents running: 21 Democrats hoping to hold U.S. House district two, two state Supreme Court and three Court of Appeals seats, four state Senate and eight state House seats, one county commission seat, county clerk and county treasurer; and two Republicans, President Donald Trump and state Sen. Ron Griggs of Alamogordo, whose district includes two of Doa Ana Countys 170 precincts.

Two long-time state Senate Democrats John Arthur Smith (32 years) of Deming and Mary Kay Papen (20 years) of Las Cruces, lost in the Primary, along with County Commissioner Gonzalez. Another county commissioner, Isabella Solis, was elected to the commission as a Democrat in 2016, switched to Republican in 2019 and chose to run for state representative this year instead of running for re-election to the commission.

Read more from the original source:

And they're off! Campaign signs popping up - Las Cruces Bulletin

What’s on the ballot? A rundown of races and issues facing Greene County voters on Tuesday – News-Leader

The United States has never delayed an election, even during the Civil War and World War II. USA TODAY

On Tuesday, Missouri voters will head to the polls to cast their ballots.

There are several primaries for federal,state and local races on the ballot, as well as a state constitutional amendment, and for Springfield voters, a question about fees for short-term lenders.

Greene County polling sites will have cleaning supplies, hand sanitizer and gloves on hand when residents show up to vote in the primary on Tuesday.(Photo: Nathan Papes/Springfield News-Leader)

Here's a rundown of what's on the ballot.

Primary races for Missouri governor, lieutenant governor, secretary of state, treasurer and attorney general are all up for grabs.

The Republicans running are:

Governor

Lieutenant Governor

Secretary of State

Treasurer

Attorney General

The Democrats running are:

Governor

Lieutenant Governor

Secretary of State

Treasurer

Attorney General

The Libertarian candidates running are:

Governor

Lieutenant Governor

Secretary of State

Treasurer

Attorney General

Green Party candidates running are:

Governor

Lieutenant Governor

Secretary of State

Treasurer

There is one Constitution Party candidate, Paul Venable, who is running for secretary of state.

The only federal nomination up for grabs in this election is oneencompassing Greene, Polk, Christian, Taney, Stone, Barry, McDonald, Newton, Jasper and Lawrence counties, as well as the southwest corner of Webster County.

The Republicans running are:

Democrat Teresa Montseny is running unopposed in her party's primary, as isLibertarian candidate Kevin Craig.

Several Greene County state seats are up for grabs this election. If you don't know your district, you can find out athttps://house.mo.gov/legislatorlookup.aspx.

District 130

There are three Republicans running for this open seat, which covers Republic, Willard and western Greene County.They are:

Democrat Dave Gragg is running unopposed in his party's primary.

District 131

There are two Republican candidates running for this open seat, which covers northern Springfield and north-central Greene County. They are:

Democrat Allison Schoolcraft is unopposed in her party's primary.

District 132

Both incumbent Democrat Crystal Quade and Republican Sarah Semple are running unopposed in their primaries for this seat, which covers parts of north and northwest Springfield.

District 133

Both incumbent Republican Curtis Trent and Democratic candidate Cindy Slimp are running unopposed in their primaries for this seat, which includes west and southwest Springfield and extends down to the cityof Battlefield.

District 134

There are two Republican candidates running for this open seat, which covers south-central Springfield, running from Bass Pro Shops to the James River. They are:

Democrat Derrick Nowlin is running unopposed in his party's primary.

District 135

Incumbent Republican Steve Helms,Democratic candidate Betsy Fogle and Green Party candidate Vicke Keplingare each running unopposed in their primaries for this seat, which covers east Springfield.

District 136

Incumbent Republican Craig Fishel and Democratic candidate Jeff Munzinger are each running unopposed in their primaries for this seat, which covers southeast Springfield and Greene County.

District 137

Incumbent Republican John F. Black and Democratic candidate Raymond Lampert are each running unopposed in their primaries for this district, which covers parts of northeast Greene County and western Webster County.

There are several county races up for grabs on the ballot.

Greene County Sheriff Jim Arnott, Treasurer Justin Hill and Public Administrator Sherri Eagon Martin,allRepublicans, are running unopposed.

District 1 Commissioner

Two people are running on the Republican ballot for the first commission district, which covers Western Greene County. They are:

Democratic candidate Wes Zongker is running unopposed in his party's primary.

District 2 Commissioner

Incumbent Republican John Russell and Libertarian candidate Cecil A. Ince are each running unopposed in their party's primaries.

Assessor

There are three Republican candidates running for Greene County Assessor. They are:

Constitutional amendment No. 2

This issue will go to all voters across the state, asking whether they want to amend the state's constitution to allow people from 19 to 64 who have an income level at or less than 133 percent of the federal poverty line to qualify for health care coverage.

The debate about expansion has been lengthy, but a News-Leader series examining the impact found:

When voters go to the ballot box, they should mark"Yes" if they support expansion, or "No" if they don't. That ballot language is as follows:

"Do you want to amend the Missouri Constitution to:

State government entities are estimated to have one-time costs of approximately $6.4 million and an unknown annual net fiscal impact by 2026 ranging from increased costs of at least $200 million to savings of $1 billion. Local governments expect costs to decrease by an unknown amount."

City of Springfield Question 1

Voters in the city of Springfield will also consider their own ballot initiative, which would require short-term lending establishments, such as payday or car title lenders, to pay an annual registration fee of $5,000.

The proposal,which city voters will see on the Aug. 4 ballot,was approved in May by City Council along with a bill requiring lenders toadvertise interest rates, disclose how long it will take people to pay off a loan and provide clear explanations about the agreement the borrower is signing.

The fee is intended to make sure lenders comply with city requirements, and the money will be used to provide alternatives to short-term lenders, help people get out of debt and educate the community about the reality of taking out a payday or car title loan.

Voters who support imposing the fee should vote "Yes," and those who don't should vote "No."The ballot language is as follows:

"Shall the City of Springfield, Missouri, be authorized to impose a fee for a Short-Term Loan Establishment permit in the amount of $5,000 annually, new or renewal, or $2,500 for a permit issued with less than 6 months remaining in the calendar year?"

Polling places citywide are open from 6 a.m. to 7p.m. Tuesday.

To find your polling place, visithttps://greenecountymo.gov/county_clerk/election/precinct_information.phpor call 417-868-4060.

Voters should remember to bring a valid state or federal ID with them to the polling place, such as a driver's license, military ID or passport.

If you don't have a government-issued ID, youcan bring a voter registration card, a Missouri university, college, vocational or technical school ID or a current utility bill, bank statement, government check, paycheck or other government document containing yourname and address.

People voting in the city should also remember to wear a mask, which is required by ordinance. Hand sanitizer and other cleaning supplies will also be available at polling places.

Katie Kull covers local government for the News-Leader. Got a story to tell? Give her a call at 417-408-1025 or email herat kkull@news-leader.com. You can also support local journalism atNews-Leader.com/subscribe.

Read or Share this story: https://www.news-leader.com/story/news/local/ozarks/2020/08/01/primary-election-missouri-ballot-greene-county/5539124002/

The rest is here:

What's on the ballot? A rundown of races and issues facing Greene County voters on Tuesday - News-Leader

Messenger: From COVID to Medicaid expansion, Missouri governor’s race revolves around health care – STLtoday.com

Its that process that creates the dichotomy Silvey lamented. The reason that lawmakers are out of touch with statewide voters isnt just because of the states longstanding rural-urban divide, its also because they long ago gerrymandered legislative districts to protect incumbent Republicans. Doing so made the districts look less like their actual communities and created primaries where, in most cases, only the most extreme Republican could win.

There are very few legislative districts left in Missouri that could elect a thoughtful Republican voice like Silvey or Barnes, and that puts the state at a loss.

So in November, as Parson is running from his COVID-19 record and his opposition to providing health care to the working poor, the bipartisan coalition that passed Medicaid, passed the minimum wage, fought right-to-work and supported medical marijuana, will be back to defend Clean Missouri.

I think you will see similar voices of support, for the Vote No on Amendment 3 campaign that Missouri saw with Medicaid expansion, says political strategist Sean Nicholson, who is getting the Clean Missouri band back together. There will be business and labor groups and community groups. There is a disconnect between what the Legislature has been working on and where the people are at.

The people, says Silvey, want health care. They want the government to solve problems. Yes, even Republicans. Medicaid expansion passed overwhelmingly in Kansas City, St. Louis and Columbia, but it also passed in the two Republican hotbeds of St. Charles County and Green County.

See the original post:

Messenger: From COVID to Medicaid expansion, Missouri governor's race revolves around health care - STLtoday.com

COVID-19 and Maine’s budget crisis require action on health care costs – Bangor Daily News

Gov. Janet Mills has led Maines response to the health crisis with compassion and clarity. Yet Maine is not immune from the seismic impacts of COVID-19. A $1.4 billion budget shortfall is estimated over the next three years, including a loss of more than $520 million this fiscal year. Maine holds the unsavory distinction of the greatest racial disparity in COVID-19 infection rates, with Black Mainers more than 20 times more likely to contract the virus than their white neighbors. A recent report shows 14,000 Mainers will be newly uninsured after tens of thousands have lost employer-provided insurance since February.

Health insurance companies are proposing raising rates for small businesses, with initial filings showing the highest requested increase for 2021 topping out at over 10 percent, following rate hikes in the double-digits last year for many plans. The Maine Health Data Organization reports that overall, the 25 most costly drugs in Maine increased in cost by nearly 11 percent last year and the cost per person increased by 27 percent. In 2018, Maines per-capita health expenditures were 10 percent higher than the U.S. average.

Our most recent polling shows over two-thirds of Mainers are concerned about not being able to afford health coverage, copays and deductibles. Nearly three quarters are concerned about prescription drug prices, with two out of three worried they wont be able to afford the medicine they need. These concerns are growing with more Mainers losing coverage.

State policymakers have taken significant steps to improve health care affordability, and this moment calls for continued action to control rising costs and expand accessibility without cutting vital access to programs. We need solutions that not only stop the spread of the virus but make sure Maine can reopen its doors and stay open. This is especially important as vulnerable Mainers return to work, caring for older Mainers and providing other essential services.

Expanded MaineCare is helping thousands access the coverage and care they need, and laws enacted last year improve affordability and access to health care in Maines individual and small business markets. Bipartisan support of measures to address skyrocketing prescription drug prices, including the creation of a Prescription Drug Affordability Board to help contain drug costs in public health programs, shows Maine policymakers can work together to address the problems we face. And that work must continue with urgency.

It starts with our federal lawmakers. Initial increases in federal match rates for state Medicaid programs have been helpful but are nowhere close to what is needed to help fill the gaps in state revenue. The HEROES Act passed by the House includes increased Medicaid funding to help avoid devastating health care cuts at the state level, but the Senates HEALS Act does not.

State policymakers have an opportunity to address rising costs with Senate President Troy Jacksons bill, LD 2110, An Act to Lower Health Care Costs. It passed in the Maine House and Senate, but sits awaiting final action as the Legislature contemplates a special session. The bill creates an independent entity to examine and identify ways to lower health care costs. It would also provide staffing to Maines Prescription Drug Affordability Board, which has only met once since its creation due in part to the lack of dedicated staff.

With an ongoing pandemic and revenue losses, reining in health care costs while also ensuring access to care has never been more important. A similar effort in Massachusetts has already produced very promising results.

There are real opportunities to protect the health care gains we have made in Maine and to help those who are going without. I am more than hopeful and confident policy makers at both the federal and state level will put politics aside and work together to protect the health and well-being of the people they represent.

Ann Woloson is the executive director of Consumers for Affordable Health Care.

More here:

COVID-19 and Maine's budget crisis require action on health care costs - Bangor Daily News

Hospital’s food delivery service is a blessing | Health Care – Grand Haven Tribune

Editors note: This is the fourth in a series celebrating our local health care workers.

I never thought spending a week in the North Ottawa Community Hospital intensive care unit with my almost 98-year-old mom would feel like such a blessing.

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm%9C@F89 E96 A2DE H66J >@> 6G6CJ 52J[ 3FE 2=D@ E96 9@?@C @7 D66:?8 E96 <:?5[ 4@>A2DD:@?2E6 2?5 4@>A6E6?E DE277 >6>36CD 2E }~rw 2E H@C<]k^Am

Donna Bullock, the service representative for North Ottawa Community Hospitals food service department, said she loves the family environment in her workplace.

kAmtG6CJ A2E:6?E ?665D ?@FC:D9>6?E[ 2?5 E96 5:2=FA 2?5 @C56CH92EJ@F H2?E A=2? @776CD 2>2K:?8 7=6I:3:=:EJ 2?5 >6?F :E6>D C2?8:?8 7C@> >256E@@C56C @>6=6EE6D[ D2?5H:496D 2?5 D@FAD E@ 32<65 7:D9[ DE62<[ DE:C 7CJ 2?5 A:KK2j 2?5 2? 23F?52?46 @7 D:56 5:D96D[ 5C:?

kAmu@@5 D6CG:46D C6AC6D6?E2E:G6 s@??2 qF==@4< @7E6? 2?DH6CD E96 dbag 6IE6?D:@? H96? H6 42== E@ A=246 2? @C56C] qF==@4<[ H9@ 92D H@C<65 2E }~rw 7@C E9C66 J62CD[ D2:5 D96 =@G6D E96 2E>@DA96C6 @7 E96 D>2==E@H? 9@DA:E2=]k^Am

kAmx =:<6 E96 72>:=J 6?G:C@?>6?E @7 E96 9@DA:E2=[ D96 D2:5] x E9:?< H6C6 C62==J =F4>F?:EJ]k^Am

Read more here:

Hospital's food delivery service is a blessing | Health Care - Grand Haven Tribune

Big Tech’s assault on free speech | TheHill – The Hill

For years, there have been whispers about Big Techs tendency to muffle those who dare to challenge mainstream liberal orthodoxy. In 2018, thePew Research Centerfound, 72% of the public thinks it likely that social media platforms actively censor political views that those companies find objectionable. By a four-to-one margin, respondents were more likely to say Big Tech supports the views of liberals over conservatives than vice versa.

As the 2020 elections approach, Big Tech has upped the ante in its limiting of free speech. This is a dangerous development that undermines the fundamental principles upon which the United States was founded. If left unchecked, it could lead to an Orwellian nightmare and, ultimately, to the end of the republic as we know it.

In the past few years, there have been countless cases of social media giants Facebook, Instagram, Twitter and YouTube muzzling conservatives and libertarians, for apparent political motives. For example, it is well documented thatTwitter uses shadow bansto prevent users from sharing their posts to the hundreds of millions of Twitter users.

Somehow,shadow bans overwhelmingly have been applied to those on the rightend of the political spectrum. Coincidence? I think not.

Although those on the left claim this is exaggerated, it happens all the time. And it seems that Twitter and others are clamping down more and more on prominent users who have the audacity to question the so-called consensus on a variety of issues.

Recently, Twitter has come under increased scrutiny because it has targeted conservatives such asDonald Trump Jr.who have posted material that question mainstream narrative about protests, coronavirus treatments, the wisdom of lockdowns and several other pressing issues.

The Trump Jr. case is particularly spine-chilling because all the presidents son did was post a video from a group of doctors who presented a case for using hydroxychloroquine as a treatment for COVID-19. According to Twitter, Tweets with the video are in violation of our Covid-19 misinformation policy. We are taking action in line with our policy here.

Shortly after, Facebook and YouTube also scrubbed the video. Although this may seem like no big deal, it certainly is.

In 2020,most Americans receive their news via social media. The sheer power held by these companies concerning the flow of information is mind-boggling. And they can use their power to shift public opinion, as demonstrated in the 2010 election whenFacebook launched a get-out-the-vote campaignthat it claims resulted in 343,000 more voters going to the polls.

If Facebook and other social media giants can nudge Americans to vote, how long before they also shift public opinion in the direction they desire? It seems as if this Rubicon may have already been crossed.

In some ways, Google has more power over information than the social media companies because Google completely dominates internet searches. Over the past year,Googles market share of worldwide internet searches has hovered around 92 percent.

According to a recentstudytitled An analysis of political bias in search engine results, Googles top search results were almost 40% more likely to contain pages with a Left or Far Left slant than they were pages from the right. Moreover, 16% of political keywords contained no right-leaning pages at all within the first page of results.

In other words, according to that study, Googles algorithm is politically biased to favor the left over the right. Maybe that explains why Google and other Big Tech companies contribute so much money to the Democratic Party compared to the Republican Party.

According to the Center for Responsive Politics,70 percentof donations by Facebook and its employees in the 2020 campaign cycle have gone to Democrats. Eighty-one percent of Googles political contributions have gone to Democrats. The same trend applies to Amazon (74 percent) and Apple (91 percent).

Fortunately, Big Techs bias is becoming more and more apparent. Most Americans are well aware that in general, Big Tech favors leftwing causes, politicians and opinions.

Since it seems that Congress is unwilling to do anything about this in the near future, the question is, what can and should we the people do about it?

Chris Talgo(ctalgo@heartland.org)is an editor at The Heartland Institute.

Go here to read the rest:

Big Tech's assault on free speech | TheHill - The Hill

Influential think tank urges Govt to protect free speech in universities – The Christian Institute

The Government must legislate to ensure freedom of speech is protected in university students unions, a leading think tank has said.

A report by the influential Policy Exchange said Parliament needed to make current legislation clearer and more robust, and impress upon universities and colleges their duty to ensure academic freedom and freedom of speech.

In recent years, students unions in England have denied pro-life and Christian student groups access to funding, and facilities such as stalls at freshers fairs.

The report called for a new Director for Academic Freedom at the Office for Students to promote tolerance for viewpoint diversity in universities and students unions.

The role would encourage compliance and investigate possible breaches.

It added that guidance should be updated to ensure students unions fulfil their freedom of speech duties and universities and colleges had to be being willing to support events in the face of intimidation and threats.

Policy Exchange has called for the Government to provide examples of sanctions that universities and colleges can apply to non-complying students unions.

It stated that universities and colleges would be expected to impose such fines against individual members of the University and those groups that fail to uphold freedom of speech, including fines for Student Unions who discriminate on grounds of viewpoint.

Where a Student Union denies a student group access to services, the report says there should be a process to appeal.

Education Secretary Gavin Williamson indicated in February that the Government is ready to defend students rights to freedom of speech.

Writing in The Times, he said: If universities dont take action, the government will. If necessary, Ill look at changing the underpinning legal framework, perhaps to clarify the duties of students unions or strengthen free speech rights.

I dont take such changes lightly, but I believe we have a responsibility to do whatever necessary to defend this right.

In 2017, Balliol College of Oxford University banned the Christian Union from its Freshers Fair, because Christianity was labelled as an excuse for homophobia and certain forms of neo-colonialism.

Organiser Freddy Potts claimed that the presence of CU members would be alienating for students and constituted a microaggression, but a backlash from Balliol students forced the organising committee to back down.

Office for Students defends free speech in no-platforming row

Security guards for Oxford prof after trans activists threats

Universities launch free speech societies

Read more here:

Influential think tank urges Govt to protect free speech in universities - The Christian Institute